Jay Lichter - 14 Jun 2023 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Director, 10%+ Owner
Signature
/s/ Tighe Reardon, Attorney-in-Fact
Issuer symbol
JANX
Transactions as of
14 Jun 2023
Transactions value $
$0
Form type
4
Filing time
16 Jun 2023, 17:10:20 UTC
Previous filing
23 Jun 2022
Next filing
15 Nov 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Stock Option (right to buy) Award $0 +12,500 $0.000000 12,500 14 Jun 2023 Common Stock 12,500 $13.22 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option will vest in equal monthly installments over the 12 months following June 14, 2023, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Company's stockholders.